<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-84618" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Natriuretic Peptide B Type Test</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Novack</surname>
            <given-names>Madeline L.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zubair</surname>
            <given-names>Muhammad</given-names>
          </name>
          <aff>Indus Hospital &#x00026; Health Network</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Madeline Novack declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Zubair declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>23</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-84618.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Natriuretic peptides (NP) are key proteins that improve and regulate circulation. They are essential proteins that act on blood vessels causing them to widen or dilate.<xref ref-type="bibr" rid="article-84618.r1">[1]</xref> These peptides are expressed predominantly by cardiomyocytes of the mixed secretory-contractile phenotype in atrial and ventricular walls. In addition to regulating blood pressure,&#x000a0;NPs inhibit cardiac hypertrophy and remodeling.<xref ref-type="bibr" rid="article-84618.r2">[2]</xref> In patients with decompensated heart failure due to volume overload, a treatment-induced drop in wedge pressure is often accompanied by a rapid drop in NP levels. Measurement of NP levels might thus assist with hemodynamic assessment and subsequent treatment titration.<xref ref-type="bibr" rid="article-84618.r3">[3]</xref>&#x000a0;NPs can also be found in the kidneys and can cause this essential organ to excrete more water and salt.<xref ref-type="bibr" rid="article-84618.r4">[4]</xref>&#x000a0;</p>
        <p>The b-type natriuretic peptide (BNP) was initially identified in porcine brain tissue in 1988 and was previously referred to as the &#x0201c;brain natriuretic peptide.&#x0201d; Later, researchers determined that the primary site of its release&#x000a0;is cardiac ventricular cells, particularly in response to ventricular distention.<xref ref-type="bibr" rid="article-84618.r5">[5]</xref> Following this discovery, abundant literature emerged regarding utilizing BNP as a potential biomarker to measure the presence and severity of heart failure.<xref ref-type="bibr" rid="article-84618.r6">[6]</xref></p>
        <p>B-type natriuretic peptide (BNP) is a member of a family of natriuretic peptides (NP) that include atrial natriuretic peptide (ANP), C-type natriuretic peptide, D-type natriuretic peptide, and urodilatin.<xref ref-type="bibr" rid="article-84618.r7">[7]</xref> Pro-BNP is a 108&#x02013;amino acid precursor protein of BNP found in the ventricles and atria of the heart.&#x000a0;Human ANP and BNP are encoded by genes located on chromosome 1.<xref ref-type="bibr" rid="article-84618.r8">[8]</xref> In situations of volume overload and myocardial muscle stretching, proBNP is upregulated at the genomic level.<xref ref-type="bibr" rid="article-84618.r9">[9]</xref></p>
        <p>A small amount of BNP is found in the cytoplasmic granules of myocytes. Upon stimulation for production and release, proBNP is cleaved by corin to equimolar amounts of the biologically active BNP hormone and the biologically inactive amino-terminal proBNP (NT-proBNP), which is also released into circulation as the unprocessed precursor protein.<xref ref-type="bibr" rid="article-84618.r8">[8]</xref> When the effects of this peptide are evaluated on vascular smooth muscle cells, cardiac fibroblasts, and myocytes, this peptide did not appear to have any biological activity.<xref ref-type="bibr" rid="article-84618.r10">[10]</xref></p>
        <p>The C-type&#x000a0;natriuretic peptide is synthesized primarily in the central nervous system. It is also found in vascular endothelial cells and may play a role in the local regulation of vascular tone.<xref ref-type="bibr" rid="article-84618.r11">[11]</xref> Unlike ANP and BNP, the human gene encoding CNP,&#x000a0;<italic toggle="yes">NPPC</italic>, is not located on chromosome 1 but on chromosome 2. In normal human subjects, the mean CNP concentration is very low (1 fmol/mL).<xref ref-type="bibr" rid="article-84618.r12">[12]</xref> It is elevated in patients with heart failure, although to a much lower extent than ANP and BNP.&#x000a0;The clearance of CNP-22 in human plasma is very rapid, with a calculated half-life of 2.6 minutes.<xref ref-type="bibr" rid="article-84618.r13">[13]</xref></p>
        <p>The natriuretic peptide system consists of&#x000a0;3 receptors: natriuretic peptide receptor-A (NPR-A), natriuretic peptide receptor-B (NPR-B), and natriuretic peptide receptor-C (NPR-C).<xref ref-type="bibr" rid="article-84618.r14">[14]</xref> The human NPR-A gene is located on chromosome 1q21&#x02013;22 and consists of 22 exons and 21 introns within 16 kilobases. The human NPR-B gene is located on chromosome 9p12&#x02013;21, and the murine version,&#x000a0;<italic toggle="yes">Npr2</italic>, is located on chromosome 4. The human NPR-C gene is located on chromosome 5p13&#x02013;14 and contains 8 exons and 7 introns spanning more than 65 kilobases.<xref ref-type="bibr" rid="article-84618.r15">[15]</xref> The&#x000a0;natriuretic peptide receptors NPR-A and NPR-B catalyze the synthesis of a classic intracellular second messenger, cyclic guanosine monophosphate or cGMP. cGMP binds to proteins such as cGMP-dependent protein kinases, cGMP-binding phosphodiesterases, and cyclic nucleotide-gated ion channels.<xref ref-type="bibr" rid="article-84618.r16">[16]</xref> NPR-C controls the concentrations of NPs through receptor-mediated internalization and degradation. The NPR-A to NPR-C ratio plays a role in regulating the biological activity of natriuretic peptides (NP).<xref ref-type="bibr" rid="article-84618.r17">[17]</xref></p>
      </sec>
      <sec id="article-84618.s2" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>BNP is a 32&#x02013;amino acid peptide hormone with a molecular weight of 3472 daltons.<xref ref-type="bibr" rid="article-84618.r6">[6]</xref> The molecule consists of an N-terminal tail of 9 amino acids, a C-terminal tail of 6 amino acids, and a 17-member ring closed by a disulfide bond between two cysteine residues. Eleven amino acids found in the ring are conserved across the family of natriuretic peptides.<xref ref-type="bibr" rid="article-84618.r18">[18]</xref> BNP binds to natriuretic peptide receptors A and C, causing the loss of water and electrolytes, vasodilation, and inhibition of the renin-angiotensin-aldosterone axis (RAAS).<xref ref-type="bibr" rid="article-84618.r19">[19]</xref> BNP is cleared from the circulation by neutral endopeptidases. The first two amino acids from the N-terminal sequence (serine and proline) are removed by dipeptidyl peptidase IV very soon after BNP is released into circulation.<xref ref-type="bibr" rid="article-84618.r7">[7]</xref></p>
        <p>Following systemic secretion, the natriuretic peptides activate transmembrane guanylate cyclases on the surface endothelial cells, thereby increasing intracellular levels of cyclic guanosine monophosphate (cGMP), leading to vasodilation. Other systemic effects&#x000a0;include diuresis and natriuresis, resulting in lowered blood pressure.<xref ref-type="bibr" rid="article-84618.r20">[20]</xref> The peptides have also demonstrated the ability to antagonize adverse pathways that are over-activated in the setting of heart failure, for example, RAAS, which has anti-diuretic effects, and the transforming growth factor-beta pathway, which increases cardiac remodeling and fibrosis.<xref ref-type="bibr" rid="article-84618.r21">[21]</xref></p>
        <p>Expression of the BNP gene is a feature of both atrial and ventricular myocytes. In the normal heart, the main site of BNP expression is in the atrial regions. Ventricular BNP gene expression increases drastically in cardiac diseases affecting the ventricles, such as heart failure (HF).<xref ref-type="bibr" rid="article-84618.r22">[22]</xref> Observing ventricular BNP gene expression in ventricular disease may have given rise to the common statement that BNP is predominantly a ventricular hormone. However, atrial and ventricular myocytes differ considerably concerning their endocrine phenotypes, and it is reasonable to expect significant differences in peptide storage and secretion patterns.<xref ref-type="bibr" rid="article-84618.r23">[23]</xref> Atrial granules contain both intact precursors and biosynthetic end products, that is, bioactive ANP-28 and BNP-32. In contrast, normal ventricular myocytes do not seem to express such granules, and normal ventricular myocytes do not contain proBNP-derived peptides.<xref ref-type="bibr" rid="article-84618.r24">[24]</xref></p>
        <p>The estimated half-life of BNP is about 20 minutes, whereas NT-proBNP has a half-life of&#x000a0;120 min; this difference explains why NT-proBNP serum levels are approximately six times higher than BNP levels, even though both molecules are released in equimolar proportions.<xref ref-type="bibr" rid="article-84618.r25">[25]</xref> Like BNP,&#x000a0;NT-proBNP concentrations vary by age; the normal threshold for those under 50 years of age is 450 pg/mL, while it is 900 pg/mL for those greater than 50 years of age.<xref ref-type="bibr" rid="article-84618.r26">[26]</xref> The clinical importance of measuring one peptide over the other has not yet been demonstrated.</p>
        <p>BNP production in cardiomyocytes is significantly increased by inflammatory cytokines such as interleukin-1-beta,&#x000a0;an effect that is markedly increased when fibroblasts are present; inflammatory cytokines directly stimulate BNP production in the heart independent of hemodynamics.<xref ref-type="bibr" rid="article-84618.r27">[27]</xref> This phenomenon is not seen with ANP. In clinical practice, plasma BNP levels will be higher in patients with myocarditis than expected solely from the hemodynamics.<xref ref-type="bibr" rid="article-84618.r28">[28]</xref></p>
      </sec>
      <sec id="article-84618.s3" sec-type="Specimen Requirements and Procedure">
        <title>Specimen Requirements and Procedure</title>
        <p>The b-type natriuretic peptide (BNP) is labile and must be collected into tubes containing EDTA and tested ideally within four hours of collection. Serum samples and citrated or heparinized plasma cannot be used. BNP can be stored for up to 24 hours at 2^oC to 8^oC for some assays.<xref ref-type="bibr" rid="article-84618.r29">[29]</xref> BNP is degraded by contact activation of the blood coagulation system&#x000a0;and can be stabilized by storage under frozen conditions or by adding kallikrein protease inhibitors.<xref ref-type="bibr" rid="article-84618.r30">[30]</xref>&#x000a0;In contrast, NT-proBNP is much more stable than BNP and can be kept at refrigerated temperatures for three days. NT-proBNP can be tested in serum and plasma collected in either heparin or EDTA. When EDTA plasma is used, NT-proBNP concentration is about 10% lower than for serum or lithium heparin.<xref ref-type="bibr" rid="article-84618.r31">[31]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-84618.s4" sec-type="Testing Procedures">
        <title>Testing Procedures</title>
        <p>Both BNP and NT-proBNP levels can be tested through standard blood draws. There are also point-of-care BNP assays, which take approximately fifteen minutes for results and are often helpful in emergent settings.<xref ref-type="bibr" rid="article-84618.r32">[32]</xref>&#x000a0;BNP and NT-proBNP are determined by several different immunoassays using antibodies directed to different epitopes on the antigen molecules.<xref ref-type="bibr" rid="article-84618.r33">[33]</xref></p>
        <p>Before introduction into clinical practice, BNP and NT-proBNP assays must be characterized with respect to the following pre-analytical and analytical issues:<xref ref-type="bibr" rid="article-84618.r34">[34]</xref></p>
        <p>
<bold>Pre-Analytical</bold>
</p>
        <p>a. Effect of storage time and temperatureb. Influence of different anticoagulantsc. Influence of gel separator tubesd. Plastic blood collection tubes are necessary for BNP; for NT-proBNP, either glass or plastic is acceptable</p>
        <p>
<bold>Analytical</bold>
</p>
        <p>a. Identification of both antibody recognition epitopesb. Cross-reactivity characteristics with related natriuretic peptides, including NT-pro ANP, ANP, CNP, BNP, and glycosylated and nonglycosylated NTproBNP and proBNPc. Identification of interferences from heterophile antibodies, rheumatoid factors, and human antimouse antibodiesd. Description of calibration material used, how the material was defined, and the concentration value assignede. Clarification of dilution responses</p>
      </sec>
      <sec id="article-84618.s5" sec-type="Interfering Factors">
        <title>Interfering Factors</title>
        <p>BNP and NT-proBNP levels may be affected by specific comorbidities, such as chronic renal failure, type 2 diabetes mellitus, obesity, and acute coronary syndrome (ACS).<xref ref-type="bibr" rid="article-84618.r23">[23]</xref> Levels&#x000a0;are higher in patients with renal failure, diabetes, and ACS and lower in patients with obesity.<xref ref-type="bibr" rid="article-84618.r7">[7]</xref>&#x000a0;Decreasing renal function with age may be partly responsible for the increase in BNP/NT-proBNP. In the absence of heart failure, the concentration of BNP/NT-proBNP increases in patients with a decreasing glomerular filtration rate.<xref ref-type="bibr" rid="article-84618.r35">[35]</xref> It is also possible that elderly subjects who appear healthy may have declining cardiac function not detectable by current noninvasive techniques.<xref ref-type="bibr" rid="article-84618.r36">[36]</xref></p>
        <p>The body mass index (BMI) is another variable influencing the reference intervals for BNP and NT-proBNP. Patients with a BMI in the obese range have lower BNP and NT-proBNP concentrations than patients with a normal or underweight BMI. There have been several theories as to the mechanism for these observations.<xref ref-type="bibr" rid="article-84618.r37">[37]</xref> Natriuretic peptide receptors are found in high concentrations in adipose tissues, suggesting that BNP is degraded. However, this does not account for the obesity effect seen for NT-proBNP, which is not degraded by these receptors.<xref ref-type="bibr" rid="article-84618.r38">[38]</xref> Therefore, comparisons of levels among patients are less meaningful than tracking the peptide trajectory of an individual patient.<xref ref-type="bibr" rid="article-84618.r39">[39]</xref></p>
        <p>All immunoassays for BNP and NT-proBNP are heterogeneous, using a separation step between bound and free antibodies; there are no problems with photometric interferents such as hemoglobin, bilirubin, or lipemia.<xref ref-type="bibr" rid="article-84618.r40">[40]</xref>&#x000a0;The cross-reactivity of assays for BNP and NT-proBNP towards proBNP is an important consideration since it is now known that proBNP also circulates in the blood of patients with heart failure.<xref ref-type="bibr" rid="article-84618.r41">[41]</xref> Because proBNP is the precursor protein to both BNP and NT-proBNP, the epitopes used to raise antibodies for these latter two peptides are also present in the proBNP peptide structure.<xref ref-type="bibr" rid="article-84618.r42">[42]</xref>&#x000a0;</p>
        <p>proBNP also exists in the blood of heart failure patients as an O-linked glycoprotein. There are seven potential glycosylation sites from the center of the molecule (from the non-BNP amino acid sequences).<xref ref-type="bibr" rid="article-84618.r43">[43]</xref>&#x000a0;There have been studies that have tested the cross-reactivity of proBNP towards commercial BNP and NT-proBNP assays. For BNP, the cross-reactivity ranged from 17% to 38% for glycosylated proBNP and 5% to 14% for non-glycosylated proBNP.<xref ref-type="bibr" rid="article-84618.r44">[44]</xref>&#x000a0;For NT-proBNP, the cross-reactivity ranged from 29% to 249%&#x000a0;for non-glycosylated proBNP but with no cross-reactivity towards glycosylated proBNP.<xref ref-type="bibr" rid="article-84618.r45">[45]</xref></p>
        <p>The relative composition of blood with regard to the various BNP, NT-proBNP, proBNP, and glycosylated forms present in the blood of patients with heart failure is not known.<xref ref-type="bibr" rid="article-84618.r46">[46]</xref> Therefore, comparing the results of different markers and different assays of the same marker will be difficult.<xref ref-type="bibr" rid="article-84618.r8">[8]</xref>&#x000a0;The clinical significance of the presence of HAMA and heterophile antibodies is diminished for BNP and NT-proBNP assays; mild false-positive results do not have significant clinical implications.<xref ref-type="bibr" rid="article-84618.r47">[47]</xref></p>
      </sec>
      <sec id="article-84618.s6" sec-type="Results, Reporting, and Critical Findings&#x0000d;&#x0000a;">
        <title>Results, Reporting, and Critical Findings
</title>
        <p>BNP and NT-proBNP levels&#x000a0;increase in patients with cardiac disease due to myocardial stress and volume overload.<xref ref-type="bibr" rid="article-84618.r42">[42]</xref> Patients with a BNP elevation of over 100 pg/mL should be assessed further for the signs and symptoms of cardiac disease.<xref ref-type="bibr" rid="article-84618.r48">[48]</xref> Though BNP is traditionally used in the diagnosis of left ventricular systolic function, it can be elevated through other processes as well; for example, right ventricular failure, acute myocardial infarction, congenital heart disease, and valvular disease.<xref ref-type="bibr" rid="article-84618.r6">[6]</xref>&#x000a0;</p>
        <p>Other situations in which natriuretic peptides are elevated include any disease that increases blood volume and thus wall stress, such as sepsis, anemia, renal dysfunction, Cushing syndrome, hyperaldosteronism, hypertension with left ventricular hypertrophy, and cirrhosis.<xref ref-type="bibr" rid="article-84618.r49">[49]</xref> In healthy individuals, BNP levels vary by age and genetic sex; levels increase with age and are higher on average in&#x000a0;females than males.<xref ref-type="bibr" rid="article-84618.r34">[34]</xref></p>
        <p>Circulating levels of natriuretic peptides increase after acute myocardial infarction; the extent of the increase is related to the size of the infarct.<xref ref-type="bibr" rid="article-84618.r50">[50]</xref> Patients with smaller infarcts tend to have a monophasic increase in plasma BNP, peaking at 20 hours after the onset of symptoms; on the other hand, those with larger infarcts, lower ejection fraction, and clinical signs of heart failure may present a further peak at five days after admission.<xref ref-type="bibr" rid="article-84618.r51">[51]</xref></p>
        <p>A value of less than 100 pg/mL for BNP and less than 300 pg/mL for NT-proBNP makes the diagnosis of heart failure less likely in an acutely dyspneic patient.<xref ref-type="bibr" rid="article-84618.r52">[52]</xref> Elevated levels of natriuretic peptides are associated with poor long-term prognosis and have an adverse impact on long-term mortality in patients with heart failure&#x000a0;and various other conditions such as coronary artery disease and atrial fibrillation.<xref ref-type="bibr" rid="article-84618.r53">[53]</xref></p>
      </sec>
      <sec id="article-84618.s7" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>
<bold>Heart Failure</bold>
</p>
        <p>The strongest indication for BNP measurement is distinguishing between cardiogenic and non-cardiogenic causes of dyspnea in an emergent setting.&#x000a0;Dyspnea is a symptom in nearly all cases of HF exacerbation. However, it is not specific to HF and may result from other pathologic processes.<xref ref-type="bibr" rid="article-84618.r54">[54]</xref>&#x000a0;The sensitivity of BNP in HF is approximately 97%. Therefore a normal BNP level (less than 100 pg/mL) virtually excludes heart failure and should prompt a search for noncardiac causes of dyspnea. An elevated level may indicate the presence of cardiac disease and the need for further cardiac workup, such as echocardiography, to determine the etiology of the patient's symptoms.<xref ref-type="bibr" rid="article-84618.r32">[32]</xref>&#x000a0;Furthermore, short-term elevations in hospitalized patients with HF have correlated with longer hospital stays.</p>
        <p>BNP can also be a useful prognostic marker in patients with known chronic heart failure; elevated levels&#x000a0;are found in patients with&#x000a0;higher New York Heart Association functional class scores and correlate with mortality, morbidity, and recurrent hospital admission.<xref ref-type="bibr" rid="article-84618.r20">[20]</xref><xref ref-type="bibr" rid="article-84618.r55">[55]</xref>&#x000a0;Furthermore, in hospitalized&#x000a0;patients&#x000a0;with heart failure, short-term elevations in BNP have been shown to predict increased hospital stays.<xref ref-type="bibr" rid="article-84618.r56">[56]</xref></p>
        <p>
<bold>Acute Coronary Syndrome</bold>
</p>
        <p>Left ventricular dysfunction due to cardiac remodeling is a significant cause of mortality following myocardial infarction (MI). BNP monitoring can help assess prognosis following MI because it becomes elevated in patients with post-MI left ventricular dysfunction with ejection fractions less than 40%.<xref ref-type="bibr" rid="article-84618.r57">[57]</xref></p>
        <p>
<bold>Limitations</bold>
</p>
        <p>While BNP is a useful tool in assessing prognosis in patients with cardiac disease, it has not been well established that BNP-guided therapy offers improved outcomes compared to symptom-guided therapies.<xref ref-type="bibr" rid="article-84618.r54">[54]</xref> Therefore, knowledge of BNP levels may predict outcomes but does not yet dictate treatment in the chronic management of heart failure. For this reason, BNP should not be used as a stand-alone test when guiding therapy in cardiac disease. Furthermore, while elevated BNP levels are highly sensitive to heart failure, they are not specific to its cause; elevated BNPs may be seen in various cardiac and noncardiac diseases, as previously mentioned. Therefore, evaluating abnormal BNP levels with further cardiac testing is necessary.<xref ref-type="bibr" rid="article-84618.r57">[57]</xref> Particular care is needed&#x000a0;when interpreting an elevated BNP in patients with multiple comorbidities, such as those with renal failure, to identify the cause of the elevation.<xref ref-type="bibr" rid="article-84618.r19">[19]</xref></p>
        <p>
<bold>Relevance&#x000a0;</bold>
</p>
        <p>Heart failure is a significant and growing cause of morbidity and mortality in the United States; it is the&#x000a0;leading cause of hospitalization in those aged 65 and older and is responsible for 10% of all healthcare expenditures.<xref ref-type="bibr" rid="article-84618.r56">[56]</xref>&#x000a0;Many symptoms of&#x000a0;heart failure&#x000a0;exacerbations are not specific to the disease process; therefore, identifying a biomarker that could assist in&#x000a0;the&#x000a0;diagnosis process was critical.&#x000a0;BNP&#x000a0;measurement&#x000a0;is a highly sensitive, low-cost, and rapid test that can be utilized in hospitals to assist in diagnosing heart failure.<xref ref-type="bibr" rid="article-84618.r58">[58]</xref></p>
      </sec>
      <sec id="article-84618.s8" sec-type="Quality Control and Lab Safety&#x0000d;&#x0000a;">
        <title>Quality Control and Lab Safety
</title>
        <p>For non-waived tests, laboratory regulations require, at the minimum, analysis of at least two levels of control materials once every 24 hours. If necessary, laboratories can assay QC samples more frequently to ensure accurate results. Quality control samples should be assayed after calibration or maintenance of an analyzer to verify the correct method performance.<xref ref-type="bibr" rid="article-84618.r59">[59]</xref>&#x000a0;To minimize QC when performing tests for which manufacturers&#x02019; recommendations are less than those required by the regulatory agency (such as once per month), the labs can develop an individualized quality control plan (IQCP) that involves performing a risk assessment of potential sources of error in all phases of testing and putting in place a QC plan to reduce the likelihood of errors.<xref ref-type="bibr" rid="article-84618.r60">[60]</xref></p>
        <p>Westgard multi-rules are used to evaluate the quality control runs. If a run is declared out of control, investigate the system (instrument, standards, controls, etc.) to determine the cause of the problem. Do not perform any analysis until the problem has been resolved.<xref ref-type="bibr" rid="article-84618.r61">[61]</xref></p>
        <p>Consider all specimens, control materials, and calibrator materials as potentially infectious. Exercise the usual precautions required for handling all laboratory reagents. Disposal of all waste material should be in accordance with local guidelines. Wear gloves, a lab coat, and safety glasses when handling human blood specimens.&#x000a0;Place all plastic tips, sample cups, and gloves that come into contact with blood in a biohazard waste container.<xref ref-type="bibr" rid="article-84618.r62">[62]</xref> Discard all disposable glassware into sharps waste containers. Protect all work surfaces with disposable absorbent bench top paper, discarded into biohazard waste containers weekly or whenever blood contamination occurs. Wipe all work surfaces weekly.<xref ref-type="bibr" rid="article-84618.r63">[63]</xref></p>
      </sec>
      <sec id="article-84618.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>From clinicians on through nursing staff, pharmacists, and other ancillary staff, all healthcare practitioners should understand&#x000a0;BNP values commensurate with their function in providing patient care. This is particularly true for those in emergent settings who may encounter patients in need of prompt intervention for cardiac-related events and conditions.</p>
      </sec>
      <sec id="article-84618.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=84618&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=84618">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/84618/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=84618">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-84618.s11">
        <title>References</title>
        <ref id="article-84618.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daniels</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Maisel</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Natriuretic peptides.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2007</year>
            <month>Dec</month>
            <day>18</day>
            <volume>50</volume>
            <issue>25</issue>
            <fpage>2357</fpage>
            <page-range>2357-68</page-range>
            <pub-id pub-id-type="pmid">18154959</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maisel</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Circulating natriuretic peptide levels in acute heart failure.</article-title>
            <source>Rev Cardiovasc Med</source>
            <year>2007</year>
            <volume>8 Suppl 5</volume>
            <fpage>S13</fpage>
            <page-range>S13-21</page-range>
            <pub-id pub-id-type="pmid">18192949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Forfia</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Watkins</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Rame</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>EP</given-names>
              </name>
            </person-group>
            <article-title>Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2005</year>
            <month>May</month>
            <day>17</day>
            <volume>45</volume>
            <issue>10</issue>
            <fpage>1667</fpage>
            <page-range>1667-71</page-range>
            <pub-id pub-id-type="pmid">15893185</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Santos-Ara&#x000fa;jo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Leite-Moreira</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pestana</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Clinical value of natriuretic peptides in chronic kidney disease.</article-title>
            <source>Nefrologia</source>
            <year>2015</year>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>227</fpage>
            <page-range>227-33</page-range>
            <pub-id pub-id-type="pmid">26299165</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koratala</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kazory</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Natriuretic Peptides as Biomarkers for Congestive States: The Cardiorenal Divergence.</article-title>
            <source>Dis Markers</source>
            <year>2017</year>
            <volume>2017</volume>
            <fpage>1454986</fpage>
            <pub-id pub-id-type="pmid">28701807</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Doust</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lehman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Glasziou</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>The role of BNP testing in heart failure.</article-title>
            <source>Am Fam Physician</source>
            <year>2006</year>
            <month>Dec</month>
            <day>01</day>
            <volume>74</volume>
            <issue>11</issue>
            <fpage>1893</fpage>
            <page-range>1893-8</page-range>
            <pub-id pub-id-type="pmid">17168346</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nakagawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nishikimi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kuwahara</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Atrial and brain natriuretic peptides: Hormones secreted from the heart.</article-title>
            <source>Peptides</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>111</volume>
            <fpage>18</fpage>
            <page-range>18-25</page-range>
            <pub-id pub-id-type="pmid">29859763</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hall</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Essential biochemistry and physiology of (NT-pro)BNP.</article-title>
            <source>Eur J Heart Fail</source>
            <year>2004</year>
            <month>Mar</month>
            <day>15</day>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>257</fpage>
            <page-range>257-60</page-range>
            <pub-id pub-id-type="pmid">14987573</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hall</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>NT-ProBNP: the mechanism behind the marker.</article-title>
            <source>J Card Fail</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>11</volume>
            <issue>5 Suppl</issue>
            <fpage>S81</fpage>
            <page-range>S81-3</page-range>
            <pub-id pub-id-type="pmid">15948107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alibay</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Beauchet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>El Mahmoud</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schmitt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brun-Ney</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Benoit</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Dubourg</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Boileau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jondeau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Puy</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Plasma N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in assessment of acute dyspnea.</article-title>
            <source>Biomed Pharmacother</source>
            <year>2005</year>
            <season>Jan-Feb</season>
            <volume>59</volume>
            <issue>1-2</issue>
            <fpage>20</fpage>
            <page-range>20-4</page-range>
            <pub-id pub-id-type="pmid">15740931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nakagawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nishikimi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>CNP, the Third Natriuretic Peptide: Its Biology and Significance to the Cardiovascular System.</article-title>
            <source>Biology (Basel)</source>
            <year>2022</year>
            <month>Jun</month>
            <day>29</day>
            <volume>11</volume>
            <issue>7</issue>
            <pub-id pub-id-type="pmid">36101368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lumsden</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Khambata</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Hobbs</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>C-type natriuretic peptide (CNP): cardiovascular roles and potential as a therapeutic target.</article-title>
            <source>Curr Pharm Des</source>
            <year>2010</year>
            <volume>16</volume>
            <issue>37</issue>
            <fpage>4080</fpage>
            <page-range>4080-8</page-range>
            <pub-id pub-id-type="pmid">21247399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r13">
          <label>13</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Yasoda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nakao</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Translational Research of the Activation of the C-Type Natriuretic Peptide (CNP)-Guanylyl Cyclase-B Pathway for Skeletal Dysplasia</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Nakao</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Minato</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Uemoto</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <source>Innovative Medicine: Basic Research and Development [Internet]</source>
            <publisher-name>Springer</publisher-name>
            <publisher-loc>Tokyo</publisher-loc>
            <year>2015</year>
            <fpage>177</fpage>
            <lpage>186</lpage>
            <pub-id pub-id-type="pmid">29787172</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Potter</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Yoder</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Flora</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Antos</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Dickey</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications.</article-title>
            <source>Handb Exp Pharmacol</source>
            <year>2009</year>
            <issue>191</issue>
            <fpage>341</fpage>
            <page-range>341-66</page-range>
            <pub-id pub-id-type="pmid">19089336</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schulz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Waldman</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>The guanylyl cyclase family of natriuretic peptide receptors.</article-title>
            <source>Vitam Horm</source>
            <year>1999</year>
            <volume>57</volume>
            <fpage>123</fpage>
            <page-range>123-51</page-range>
            <pub-id pub-id-type="pmid">10232048</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goetze</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Bruneau</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Ramos</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Ogawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>de Bold</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>de Bold</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Cardiac natriuretic peptides.</article-title>
            <source>Nat Rev Cardiol</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>17</volume>
            <issue>11</issue>
            <fpage>698</fpage>
            <page-range>698-717</page-range>
            <pub-id pub-id-type="pmid">32444692</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuwahara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nakao</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Regulation and significance of atrial and brain natriuretic peptides as cardiac hormones.</article-title>
            <source>Endocr J</source>
            <year>2010</year>
            <volume>57</volume>
            <issue>7</issue>
            <fpage>555</fpage>
            <page-range>555-65</page-range>
            <pub-id pub-id-type="pmid">20571250</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuwahara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nakagawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nishikimi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Cutting Edge of Brain Natriuretic Peptide (BNP) Research&#x03000;- The Diversity of BNP Immunoreactivity and Its Clinical Relevance.</article-title>
            <source>Circ J</source>
            <year>2018</year>
            <month>Sep</month>
            <day>25</day>
            <volume>82</volume>
            <issue>10</issue>
            <fpage>2455</fpage>
            <page-range>2455-2461</page-range>
            <pub-id pub-id-type="pmid">30135320</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Omland</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Advances in congestive heart failure management in the intensive care unit: B-type natriuretic peptides in evaluation of acute heart failure.</article-title>
            <source>Crit Care Med</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>36</volume>
            <issue>1 Suppl</issue>
            <fpage>S17</fpage>
            <page-range>S17-27</page-range>
            <pub-id pub-id-type="pmid">18158473</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abuzaanona</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lanfear</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Pharmacogenomics of the Natriuretic Peptide System in Heart Failure.</article-title>
            <source>Curr Heart Fail Rep</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>14</volume>
            <issue>6</issue>
            <fpage>536</fpage>
            <page-range>536-542</page-range>
            <pub-id pub-id-type="pmid">29075957</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dobaczewski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Frangogiannis</surname>
                <given-names>NG</given-names>
              </name>
            </person-group>
            <article-title>Transforming growth factor (TGF)-&#x003b2; signaling in cardiac remodeling.</article-title>
            <source>J Mol Cell Cardiol</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>51</volume>
            <issue>4</issue>
            <fpage>600</fpage>
            <page-range>600-6</page-range>
            <pub-id pub-id-type="pmid">21059352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ellmers</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Knowles</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Smithies</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Maeda</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cameron</surname>
                <given-names>VA</given-names>
              </name>
            </person-group>
            <article-title>Ventricular expression of natriuretic peptides in Npr1(-/-) mice with cardiac hypertrophy and fibrosis.</article-title>
            <source>Am J Physiol Heart Circ Physiol</source>
            <year>2002</year>
            <month>Aug</month>
            <volume>283</volume>
            <issue>2</issue>
            <fpage>H707</fpage>
            <page-range>H707-14</page-range>
            <pub-id pub-id-type="pmid">12124219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maries</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Manitiu</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic and prognostic values of B-type natriuretic peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP).</article-title>
            <source>Cardiovasc J Afr</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>24</volume>
            <issue>7</issue>
            <fpage>286</fpage>
            <page-range>286-9</page-range>
            <pub-id pub-id-type="pmid">24217307</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Christoffersen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Goetze</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Bartels</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Larsen</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Ribel</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Rehfeld</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Rolin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>LB</given-names>
              </name>
            </person-group>
            <article-title>Chamber-dependent expression of brain natriuretic peptide and its mRNA in normal and diabetic pig heart.</article-title>
            <source>Hypertension</source>
            <year>2002</year>
            <month>Jul</month>
            <volume>40</volume>
            <issue>1</issue>
            <fpage>54</fpage>
            <page-range>54-60</page-range>
            <pub-id pub-id-type="pmid">12105138</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pfister</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Scholz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wielckens</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Erdmann</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Use of NT-proBNP in routine testing and comparison to BNP.</article-title>
            <source>Eur J Heart Fail</source>
            <year>2004</year>
            <month>Mar</month>
            <day>15</day>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>289</fpage>
            <page-range>289-93</page-range>
            <pub-id pub-id-type="pmid">14987578</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buchner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Riegger</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Luchner</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[Clinical utility of the cardiac markers BNP and NT-proBNP].</article-title>
            <source>Acta Med Austriaca</source>
            <year>2004</year>
            <volume>31</volume>
            <issue>4</issue>
            <fpage>144</fpage>
            <page-range>144-51</page-range>
            <pub-id pub-id-type="pmid">15732251</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fish-Trotter</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ferguson</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Arora</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Bachmann</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Daniels</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Reilly</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Lima</surname>
                <given-names>JAC</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>DK</given-names>
              </name>
            </person-group>
            <article-title>Inflammation and Circulating Natriuretic Peptide Levels.</article-title>
            <source>Circ Heart Fail</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>13</volume>
            <issue>7</issue>
            <fpage>e006570</fpage>
            <pub-id pub-id-type="pmid">32507024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ogawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>de Bold</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>[The endocrine heart and inflammation].</article-title>
            <source>Medicina (B Aires)</source>
            <year>2013</year>
            <volume>73</volume>
            <issue>6</issue>
            <fpage>562</fpage>
            <page-range>562-6</page-range>
            <pub-id pub-id-type="pmid">24356270</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zylberman</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>[The natriuretic peptide system and its biomarkers].</article-title>
            <source>Medicina (B Aires)</source>
            <year>2014</year>
            <volume>74</volume>
            <issue>3</issue>
            <fpage>265</fpage>
            <page-range>265-6</page-range>
            <pub-id pub-id-type="pmid">24918687</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Packer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bijou</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mair</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wallentin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Feldcamp</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Haverstick</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Ahnadi</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Despres</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bluestein</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ghani</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study.</article-title>
            <source>Clin Chem</source>
            <year>2004</year>
            <month>May</month>
            <volume>50</volume>
            <issue>5</issue>
            <fpage>867</fpage>
            <page-range>867-73</page-range>
            <pub-id pub-id-type="pmid">15010423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lippi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Salvagno</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Montagnana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guidi</surname>
                <given-names>GC</given-names>
              </name>
            </person-group>
            <article-title>Measurement of Elecsys NT-proBNP in serum, K2 EDTA and heparin plasma.</article-title>
            <source>Clin Biochem</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>40</volume>
            <issue>9-10</issue>
            <fpage>747</fpage>
            <page-range>747-8</page-range>
            <pub-id pub-id-type="pmid">17408609</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mayo</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Colletti</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Brain natriuretic peptide (BNP) testing in the emergency department.</article-title>
            <source>J Emerg Med</source>
            <year>2006</year>
            <month>Aug</month>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>201</fpage>
            <page-range>201-10</page-range>
            <pub-id pub-id-type="pmid">17044584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clerico</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Franzini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Masotti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Prontera</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Passino</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>State of the art of immunoassay methods for B-type natriuretic peptides: An update.</article-title>
            <source>Crit Rev Clin Lab Sci</source>
            <year>2015</year>
            <volume>52</volume>
            <issue>2</issue>
            <fpage>56</fpage>
            <page-range>56-69</page-range>
            <pub-id pub-id-type="pmid">25547534</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cemin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Daves</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pre-analytic variability in cardiovascular biomarker testing.</article-title>
            <source>J Thorac Dis</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>7</volume>
            <issue>10</issue>
            <fpage>E395</fpage>
            <page-range>E395-401</page-range>
            <pub-id pub-id-type="pmid">26623116</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Okamoto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hashizume</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>BNP as a Major Player in the Heart-Kidney Connection.</article-title>
            <source>Int J Mol Sci</source>
            <year>2019</year>
            <month>Jul</month>
            <day>22</day>
            <volume>20</volume>
            <issue>14</issue>
            <pub-id pub-id-type="pmid">31336656</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keyzer</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Hoffmann</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Ringoir</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nabbe</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Widdershoven</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Pop</surname>
                <given-names>VJ</given-names>
              </name>
            </person-group>
            <article-title>Age- and gender-specific brain natriuretic peptide (BNP) reference ranges in primary care.</article-title>
            <source>Clin Chem Lab Med</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>52</volume>
            <issue>9</issue>
            <fpage>1341</fpage>
            <page-range>1341-6</page-range>
            <pub-id pub-id-type="pmid">24781675</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Madamanchi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Alhosaini</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sumida</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Runge</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure.</article-title>
            <source>Int J Cardiol</source>
            <year>2014</year>
            <month>Oct</month>
            <day>20</day>
            <volume>176</volume>
            <issue>3</issue>
            <fpage>611</fpage>
            <page-range>611-7</page-range>
            <pub-id pub-id-type="pmid">25156856</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krauser</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Lloyd-Jones</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Chae</surname>
                <given-names>CU</given-names>
              </name>
              <name>
                <surname>Cameron</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Anwaruddin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Baggish</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tung</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Januzzi</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy.</article-title>
            <source>Am Heart J</source>
            <year>2005</year>
            <month>Apr</month>
            <volume>149</volume>
            <issue>4</issue>
            <fpage>744</fpage>
            <page-range>744-50</page-range>
            <pub-id pub-id-type="pmid">15990762</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bayes-Genis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lloyd-Jones</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>van Kimmenade</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Lainchbury</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Richards</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ordo&#x000f1;ez-Llanos</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Santal&#x000f3;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pinto</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Januzzi</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea.</article-title>
            <source>Arch Intern Med</source>
            <year>2007</year>
            <month>Feb</month>
            <day>26</day>
            <volume>167</volume>
            <issue>4</issue>
            <fpage>400</fpage>
            <page-range>400-7</page-range>
            <pub-id pub-id-type="pmid">17325303</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Semenov</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Feygina</surname>
                <given-names>EE</given-names>
              </name>
            </person-group>
            <article-title>Standardization of BNP and NT-proBNP Immunoassays in Light of the Diverse and Complex Nature of Circulating BNP-Related Peptides.</article-title>
            <source>Adv Clin Chem</source>
            <year>2018</year>
            <volume>85</volume>
            <fpage>1</fpage>
            <page-range>1-30</page-range>
            <pub-id pub-id-type="pmid">29655458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tamm</surname>
                <given-names>NN</given-names>
              </name>
              <name>
                <surname>Seferian</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Semenov</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Mukharyamova</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Koshkina</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Krasnoselsky</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Postnikov</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Serebryanaya</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Apple</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Murakami</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Katrukha</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Novel immunoassay for quantification of brain natriuretic peptide and its precursor in human blood.</article-title>
            <source>Clin Chem</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>54</volume>
            <issue>9</issue>
            <fpage>1511</fpage>
            <page-range>1511-8</page-range>
            <pub-id pub-id-type="pmid">18606632</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cao</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Jia</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>BNP and NT-proBNP as Diagnostic Biomarkers for Cardiac Dysfunction in Both Clinical and Forensic Medicine.</article-title>
            <source>Int J Mol Sci</source>
            <year>2019</year>
            <month>Apr</month>
            <day>12</day>
            <volume>20</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">31013779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weber</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hamm</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine.</article-title>
            <source>Heart</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>92</volume>
            <issue>6</issue>
            <fpage>843</fpage>
            <page-range>843-9</page-range>
            <pub-id pub-id-type="pmid">16698841</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luckenbill</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Christenson</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Mair</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ordonez-Llanos</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pagani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tate</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Ler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Apple</surname>
                <given-names>FS</given-names>
              </name>
            </person-group>
            <article-title>Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC Committee for Standardization of Markers of Cardiac Damage.</article-title>
            <source>Clin Chem</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>54</volume>
            <issue>3</issue>
            <fpage>619</fpage>
            <page-range>619-21</page-range>
            <pub-id pub-id-type="pmid">18310156</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clerico</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fontana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zyw</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Passino</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Emdin</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: a systematic review.</article-title>
            <source>Clin Chem</source>
            <year>2007</year>
            <month>May</month>
            <volume>53</volume>
            <issue>5</issue>
            <fpage>813</fpage>
            <page-range>813-22</page-range>
            <pub-id pub-id-type="pmid">17384013</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>ZL</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>FY</given-names>
              </name>
              <name>
                <surname>Xi</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Natriuretic peptide family as diagnostic/prognostic biomarker and treatment modality in management of adult and geriatric patients with heart failure: remaining issues and challenges.</article-title>
            <source>J Geriatr Cardiol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>15</volume>
            <issue>8</issue>
            <fpage>540</fpage>
            <page-range>540-546</page-range>
            <pub-id pub-id-type="pmid">30344534</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saenger</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Rodriguez-Fraga</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ordonez-Llanos</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Goetze</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Apple</surname>
                <given-names>FS</given-names>
              </name>
            </person-group>
            <article-title>Specificity of B-Type Natriuretic Peptide Assays: Cross-Reactivity with Different BNP, NT-proBNP, and proBNP Peptides.</article-title>
            <source>Clin Chem</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>63</volume>
            <issue>1</issue>
            <fpage>351</fpage>
            <page-range>351-358</page-range>
            <pub-id pub-id-type="pmid">28062628</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Christ</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mueller</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Use of natriuretic peptide assay in dyspnea.</article-title>
            <source>Dtsch Arztebl Int</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>105</volume>
            <issue>6</issue>
            <fpage>95</fpage>
            <page-range>95-100</page-range>
            <pub-id pub-id-type="pmid">19633758</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pfister</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Natriuretic peptides BNP and NT-pro-BNP: established laboratory markers in clinical practice or just perspectives?</article-title>
            <source>Clin Chim Acta</source>
            <year>2004</year>
            <month>Nov</month>
            <volume>349</volume>
            <issue>1-2</issue>
            <fpage>25</fpage>
            <page-range>25-38</page-range>
            <pub-id pub-id-type="pmid">15469852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Horio</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shimada</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kohno</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yoshimura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kawarabayashi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yasunari</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Murakawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yokokawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ikeda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fukui</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Serial changes in atrial and brain natriuretic peptides in patients with acute myocardial infarction treated with early coronary angioplasty.</article-title>
            <source>Am Heart J</source>
            <year>1993</year>
            <month>Aug</month>
            <volume>126</volume>
            <issue>2</issue>
            <fpage>293</fpage>
            <page-range>293-9</page-range>
            <pub-id pub-id-type="pmid">8337997</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arakawa</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aoki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hiramori</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Relationship between plasma level of brain natriuretic peptide and myocardial infarct size.</article-title>
            <source>Cardiology</source>
            <year>1994</year>
            <volume>85</volume>
            <issue>5</issue>
            <fpage>334</fpage>
            <page-range>334-40</page-range>
            <pub-id pub-id-type="pmid">7850823</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ozturk</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Unluer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Denizbasi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guneysel</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Onur</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Can NT-proBNP be used as a criterion for heart failure hospitalization in emergency room?</article-title>
            <source>J Res Med Sci</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>16</volume>
            <issue>12</issue>
            <fpage>1564</fpage>
            <page-range>1564-71</page-range>
            <pub-id pub-id-type="pmid">22973364</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ojamaa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Samuels</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gilani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>An</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>YD</given-names>
              </name>
              <name>
                <surname>Askari</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gerdes</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>BNP as a New Biomarker of Cardiac Thyroid Hormone Function.</article-title>
            <source>Front Physiol</source>
            <year>2020</year>
            <volume>11</volume>
            <fpage>729</fpage>
            <pub-id pub-id-type="pmid">32733267</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Francis</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Felker</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>WH</given-names>
              </name>
            </person-group>
            <article-title>A Test in Context: Critical Evaluation of Natriuretic Peptide Testing in Heart Failure.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2016</year>
            <month>Jan</month>
            <day>26</day>
            <volume>67</volume>
            <issue>3</issue>
            <fpage>330</fpage>
            <page-range>330-7</page-range>
            <pub-id pub-id-type="pmid">26796399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seino</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ogawa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yamashita</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fukushima</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ogata</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fukumoto</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Takano</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Application of NT-proBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure.</article-title>
            <source>Eur J Heart Fail</source>
            <year>2004</year>
            <month>Mar</month>
            <day>15</day>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>295</fpage>
            <page-range>295-300</page-range>
            <pub-id pub-id-type="pmid">14987579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Savarese</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Musella</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>D'Amore</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vassallo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Losco</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gambardella</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cecere</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Petraglia</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pagano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fimiani</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rengo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Leosco</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Trimarco</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Perrone-Filardi</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure: a meta-analysis.</article-title>
            <source>JACC Heart Fail</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>148</fpage>
            <page-range>148-58</page-range>
            <pub-id pub-id-type="pmid">24720923</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kelly</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Struthers</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Are natriuretic peptides clinically useful as markers of heart failure?</article-title>
            <source>Ann Clin Biochem</source>
            <year>2001</year>
            <month>Sep</month>
            <volume>38</volume>
            <issue>Pt 5</issue>
            <fpage>575</fpage>
            <page-range>575-83</page-range>
            <pub-id pub-id-type="pmid">11587142</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nishikimi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakagawa</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Potential pitfalls when interpreting plasma BNP levels in heart failure practice.</article-title>
            <source>J Cardiol</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>78</volume>
            <issue>4</issue>
            <fpage>269</fpage>
            <page-range>269-274</page-range>
            <pub-id pub-id-type="pmid">34088563</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Badrick</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>The quality control system.</article-title>
            <source>Clin Biochem Rev</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>29 Suppl 1</volume>
            <issue>Suppl 1</issue>
            <fpage>S67</fpage>
            <page-range>S67-70</page-range>
            <pub-id pub-id-type="pmid">18852861</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bruno</surname>
                <given-names>LC</given-names>
              </name>
            </person-group>
            <article-title>IQCP: Guideline and Helpful Tools for Implementation.</article-title>
            <source>Lab Med</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>47</volume>
            <issue>4</issue>
            <fpage>e42</fpage>
            <page-range>e42-e46</page-range>
            <pub-id pub-id-type="pmid">27708173</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Westgard</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Westgard</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Establishing Evidence-Based Statistical Quality Control Practices.</article-title>
            <source>Am J Clin Pathol</source>
            <year>2019</year>
            <month>Mar</month>
            <day>01</day>
            <volume>151</volume>
            <issue>4</issue>
            <fpage>364</fpage>
            <page-range>364-370</page-range>
            <pub-id pub-id-type="pmid">30517600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cornish</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Arambula</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Arduino</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Bryan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Burton</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dickson</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Giri</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Griffith</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Pentella</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Salerno</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Sandhu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Snyder</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Tormey</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Wagar</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Weirich</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Clinical Laboratory Biosafety Gaps: Lessons Learned from Past Outbreaks Reveal a Path to a Safer Future.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>2021</year>
            <month>Jun</month>
            <day>16</day>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>e0012618</fpage>
            <pub-id pub-id-type="pmid">34105993</pub-id>
          </element-citation>
        </ref>
        <ref id="article-84618.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pentella</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Update on Biosafety and Emerging Infections for the Clinical Microbiology Laboratory.</article-title>
            <source>Clin Lab Med</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>40</volume>
            <issue>4</issue>
            <fpage>473</fpage>
            <page-range>473-482</page-range>
            <pub-id pub-id-type="pmid">33121616</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
